EGFR G796D mutation mediates resistance to osimertinib.

Item

http://www.wikidata.org/entity/Q41472663

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

EGFR G796D mutation mediates resistance to osimertinib.

@en

type

Item

label

EGFR G796D mutation mediates resistance to osimertinib.

@en

prefLabel

EGFR G796D mutation mediates resistance to osimertinib.

@en

P1476

EGFR G796D mutation mediates resistance to osimertinib.

@en

P2093

Chunyan Wu

http://www.w3.org/2001/XMLSchema#string

Di Zheng

http://www.w3.org/2001/XMLSchema#string

Jian Ni

http://www.w3.org/2001/XMLSchema#string

Jianfang Xu

http://www.w3.org/2001/XMLSchema#string

Jiying Wang

http://www.w3.org/2001/XMLSchema#string

Li Liu

http://www.w3.org/2001/XMLSchema#string

Min Hu

http://www.w3.org/2001/XMLSchema#string

Xuehua Zhu

http://www.w3.org/2001/XMLSchema#string

Xuesong Lu

http://www.w3.org/2001/XMLSchema#string

Yu Bai

http://www.w3.org/2001/XMLSchema#string

P2860

Liquid biopsies: genotyping circulating tumor DNA

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

P304

49671-49679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17913

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28572531

http://www.w3.org/2001/XMLSchema#string

P932

5564797

http://www.w3.org/2001/XMLSchema#string